LDOS Recovers Ground as Shorts Trim and Earnings Loom

Leidos Holdings has bounced hard this week, gaining 6.6% to close at $127.66, even as the analyst community remains in a cautious crouch ahead of the November 3 earnings print.

The stock's week stands out relative to its peer group. KBR added 4% and Booz Allen Hamilton gained 3.7%, but Leidos outpaced both. CACI actually slipped 0.3% over the same period. The divergence is notable because the previous note published on October 12 documented a clear convergence of negative signals: a JP Morgan downgrade, elevated put demand, and rising borrow costs. That picture has shifted in the ten days since.

Short sellers trimmed their position into the rally. Short interest fell 3.1% over the week to 3.6% of free float, representing roughly 4.56 million shares. That is a modest position by any measure, and the borrow market reflects it: cost to borrow is just 0.46%, well within low-cost territory, and availability is extremely loose at 7,508% relative to short interest. There are far more shares available to lend than there are shorts to absorb them. The tightest the borrow market has been in the past year was back in mid-September, when availability dropped to around 1,154%. Today's reading is nowhere near that. Options positioning has also normalised: the put/call ratio is 0.50, almost exactly in line with its 20-day average of 0.50, with a z-score near zero. A week ago the ratio was running a little higher; the defensive tilt that preceded the JP Morgan downgrade has largely unwound.

The Street's stance remains measured, however. The consensus mean target is $151.73 against Tuesday's close of $127.66, implying roughly 19% upside on paper. But the direction of travel for targets has been uniformly downward since August. JP Morgan moved to Neutral from Overweight on October 8 and cut its target to $142. Citigroup kept its Buy but lowered to $141. Jefferies and TD Cowen both trimmed Hold targets to $130. Goldman Sachs, still at Neutral, cut to $132 in August. No firm in the recent cycle has raised its target. The bull case centres on the Entrust acquisition adding inorganic revenue and the company's exposure to air defence and hypersonics programmes. The bear case, as management itself acknowledged, is that Q2 2026 was expected to be the low point for margins, with federal budget uncertainty and a 0.8x book-to-bill creating near-term backlog pressure. Valuation multiples have edged up with the share price: the trailing PE is now around 10.2x and EV/EBITDA around 8.3x, both slightly higher on the week but still at undemanding levels for a defence-services name.

The most recent ORTEX earnings data shows the last quarterly print, on August 4, drove a 6.8% single-day gain and an 18.7% move over the subsequent five days. That reaction occurred against a backdrop of adjusted EPS of $3.13 versus a $2.90 consensus estimate. The November 3 print will carry a different set of expectations: the Street is now better priced for execution risk, targets have come in, and the stock is trading about $14 below its August-quarter close. How the book-to-bill trend and the Entrust integration have tracked through the September quarter are what will determine whether the week's recovery holds.